Tag:

Abbott

Latest Headlines

Latest Headlines

Boston Scientific's Synergy Stent performs well in pivotal clinical trial

Boston Scientific's Synergy bioabsorbable polymer drug-eluting stent is on track for FDA approval after the successful Evolve II clinical trial, experts said, citing data released yesterday at the American Heart Association meeting in Chicago.

Abbott creates electrophysiology biz by moving in on a trio of NEA startups

Abbott has made its move on a trio of med tech startups focused on cardiovascular catheterization. It is buying electrophysiology startup Topera for $250 million plus undisclosed milestones and has secured the right to purchase Advanced Cardiac Therapeutics, which has a novel ablation catheter. Plus, Abbott Ventures participated in a venture round for VytronUS.

Mobile blood glucose monitor startup Telcare gets $33M round

The race to the noninvasive glucose monitor is apparently passé. Right now it's all about getting glucose level data on mobile devices as well as enabling easy analysis and sharing of the data. That's what the wireless glucose monitor from Telcare does. For its efforts, Telcare got a $32.5 million Series C round.

New tax rules won't spook Mylan out of Abbott generics buy

A few potential deals have already caved under the weight of new U.S. tax rules that discourage inversion deals. Not Mylan's. The Pittsburgh-based company is pushing ahead with a $5.3 billion plan to buy a piece of Abbott Laboratories' overseas generics business--with a few edits, of course.

Med tech attorneys say FDA ramping up monitoring of device promotion

Device advice was in abundance at today's Food and Drug Law Institute panel discussion on the industry's compliance with promotion and advertising regs, featuring prominent industry lawyers from Medtronic, Covidien, Abbott and law firms.

Treasury's crackdown on inversion could scupper Medtronic-Covidien deal

Treasury Secretary Jacob Lew yesterday unveiled a plethora reforms to make tax inversion more difficult and less attractive, potentially killing a plethora of pending mergers with foreign companies, including Medtronic's $43 billion tie-up with Ireland's Covidien. 

Abbott: Absorb is comparable to drug-eluting stents

Abbott released one-year data of the first randomized controlled trial of 501 patients, comparing its clinical-stage Absorb Bioresorbable Vascular Scaffold to the company's counterpart, the Xience drug-eluting stent, yesterday at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC. 

Abbott diagnostic enables faster, cheaper infection treatment

A new study suggests that a diagnostic from Abbott Laboratories offers a more accurate and faster diagnosis of the cause of blood-related infections. The in vitro diagnostic is expected to receive a CE mark in the coming months.

Abbott glucose monitor eliminates finger sticks, receives CE mark

Getting rid of the finger stick for diabetics while maintaining sufficient accuracy without calibration is a long-held industry goal and could prove a boon to patients.

VC Rock Health partners with Abbott, expands digital health portfolio

Venture Capital firm Rock Health announced today that it is adding 8 digital health companies to its portfolio and partnering with three industry bigwigs, including Abbott.